Mikkel Holmen Andersen

Title: Mikkel Holmen Andersen: Innovator in TNF Antagonists

Introduction

Mikkel Holmen Andersen is a notable inventor based in Sporup, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of TNF antagonists. His work focuses on creating polypeptides that have improved binding characteristics and efficacy for therapeutic applications.

Latest Patents

Mikkel holds a patent for "TNF antagonists - TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy." This innovative patent includes polypeptides that comprise a TNF binding domain with the amino acid sequence KRWS-RYF (SEQ ID NO:1). The polypeptides are designed for the preparation of pharmaceutical compositions and can be used in the treatment of pathologies mediated by TNF, such as rheumatoid arthritis. He has 1 patent to his name.

Career Highlights

Mikkel is currently associated with Anaphore, Inc., where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment of inflammatory diseases, showcasing his dedication to improving patient outcomes.

Collaborations

Mikkel collaborates with talented professionals in his field, including Helle Krogh Ottow and Mette Munch. These partnerships enhance the innovative capacity of his projects and contribute to the advancement of biotechnology.

Conclusion

Mikkel Holmen Andersen is a distinguished inventor whose work on TNF antagonists represents a significant advancement in therapeutic biotechnology. His contributions are poised to make a meaningful difference in the treatment of diseases like rheumatoid arthritis.